ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2013
Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 91 citations in OpenAlex.
- Dopamine receptors in ocular surface biology: Current evidence and future directions.Indian journal of ophthalmology · 2026Review
- Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC-MS/MS.Scientific reports · 2025Article
- Exploring α-Syn's Functions Through Ablation Models: Physiological and Pathological Implications.Cellular and molecular neurobiology · 2025Review
- Potential therapeutic effects of ibudilast and retinoic acid against cuprizone-induced behavioral and biochemical changes in mouse brain.Frontiers in molecular neuroscience · 2025Article
- Quality of life in hospitalized COVID-19 patients: the role of psychosocial, inflammatory, and dopaminergic pathways.Frontiers in psychology · 2025Article
- Microbial orchestration of neuroimmune crosstalk: from homeostasis to disease.Frontiers in immunology · 2025Review
- Article
- Review
- Article
- [Role of the sympathetic nervous system in chronic inflammation].Zeitschrift fur Rheumatologie · 2023Review
- A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients.Turkish journal of medical sciences · 2022Article
- The function of gut microbiota in immune-related neurological disorders: a review.Journal of neuroinflammation · 2022Review
- Article
- The Dual Role of the βInternational journal of molecular sciences · 2022Article
- Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Review
- Th17-cells in depression: Implication in multiple sclerosis.Frontiers in immunology · 2022Review
- Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.Frontiers in neurology · 2022Review
- Social Environment Ameliorates Behavioral and Immune Impairments in Tyrosine Hydroxylase Haploinsufficient Female Mice.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021Article
- Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an autoimmune disorder of the CNS characterized by inflammation, demyelination and axonal loss. Classical evidence in experimental allergic encephalomyelitis, the animal model of MS, support the relevance of sympatoadrenergic as well as of dopaminergic mechanisms. In MS patients, dysregulation of adrenergic and dopaminergic pathways contribute to the disease in immune system cells as well as in glial cells. Available evidence is summarized and discussed also in the light of the novel role of dopamine, noradrenaline and adrenaline as transmitters in immune cells, providing a conceptual frame to exploit the potential of several dopaminergic and adrenergic agents, already in clinical use for non-immune indications and with a usually favourable risk-benefit profile, as add-on drugs to conventional immunomodulating therapies in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.